Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586952 | 0.87 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL4587361 | 0.87 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL4587022 | 0.86 | PTGS2 (0.40) | PTGS2 | |
| SCHEMBL4588076 | 0.86 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL4585890 | 0.86 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL4587527 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL4586736 | 0.80 | ALDH1A1 (0.45) | PTGS2PTGS1 | |
| SCHEMBL4587680 | 0.74 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL6513666 | 0.74 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL5908704 | 0.74 | CA2 (0.61) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556364-A4 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP (KR) | 2008-04-16 | — | — | EP | claimed |
| CN-100357282-C | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP (KR) | 2007-12-26 | — | — | CN | claimed |
| CN-1705650-A | Isothiazole derivatives, process for preparing the same, and pharmaceutical composition comprising the same | CJ CORP (KR) | 2005-12-07 | — | — | CN | claimed |
| US-6967213-B2 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2005-11-22 | — | — | US | claimed |
| EP-1556364-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ Corp. (KR) | 2005-07-27 | — | — | EP | claimed |
| WO-2004035553-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP. (KR) | 2004-04-29 | — | — | WO | claimed |
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2004-04-15 | — | — | US | claimed |
| EP-1556364-A4 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP (KR) | 2008-04-16 | — | — | EP | disclosed |
| CN-100357282-C | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP (KR) | 2007-12-26 | — | — | CN | disclosed |
| CN-1705650-A | Isothiazole derivatives, process for preparing the same, and pharmaceutical composition comprising the same | CJ CORP (KR) | 2005-12-07 | — | — | CN | disclosed |
| US-6967213-B2 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2005-11-22 | — | — | US | disclosed |
| EP-1556364-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ Corp. (KR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035553-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP. (KR) | 2004-04-29 | — | — | WO | disclosed |
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CYP3A5, CYP2C9, CYP2C19 | PTGS2 152/4885PTGS1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.